Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Kai Yao, Yong-fei Zhao & Heng-bing Zu. (2019) Melatonin receptor stimulation by agomelatine prevents Aβ-induced tau phosphorylation and oxidative damage in PC12 cells. Drug Design, Development and Therapy 13, pages 387-396.
Read now
Read now
Dan-dan Feng, Tao Tang, Xiang-ping Lin, Zhao-yu Yang, Shu Yang, Zi-an Xia, Yun Wang, Piao Zheng, Yang Wang & Chun-hu Zhang. (2016) Nine traditional Chinese herbal formulas for the treatment of depression: an ethnopharmacology, phytochemistry, and pharmacology review. Neuropsychiatric Disease and Treatment 12, pages 2387-2402.
Read now
Read now
Mélanie Brignone, Françoise Diamand, Caroline Painchault & Shweta Takyar. (2016) Efficacy and tolerability of switching therapy to vortioxetine versus other antidepressants in patients with major depressive disorder. Current Medical Research and Opinion 32:2, pages 351-366.
Read now
Read now
Ruiying Kang, Yan He, Yuxiang Yan, Zhiwu Li, Yeqing Wu, Xiaojuan Guo, Zhigang Liang & Jun Jiang. (2015) Comparison of paroxetine and agomelatine in depressed type 2 diabetes mellitus patients: a double-blind, randomized, clinical trial. Neuropsychiatric Disease and Treatment 11, pages 1307-1311.
Read now
Read now
Articles from other publishers (14)
Muhammad Naveed, Lian-Di Li, Gang Sheng, Zi-Wei Du, Ya-Ping Zhou, Sun Nan, Ming-Yi Zhu, Jing Zhang & Qi-Gang Zhou. (2022) Agomelatine: An Astounding Sui-generis Antidepressant?. Current Molecular Pharmacology 15:7, pages 943-961.
Crossref
Crossref
Fadhil A-Hamad Saleh-Arong, Nattaphon Chokemaitree, Naowanit Nata, Pamila Tasanavipas, Narittaya Varothai & Bancha Satirapoj. (2022) EFFECT OF AGOMELATINE AND SERTRALINE ON PATIENTS WITH MAJOR DEPRESSIVE DISORDERS AND CHRONIC KIDNEY DISEASE: A RANDOMIZED CONTROLLED TRIAL. Journal of Southeast Asian Medical Research 6, pages e0127.
Crossref
Crossref
Mehar Sahu, Rahul Tripathi, Niraj Kumar Jha, Saurabh Kumar Jha, Rashmi K. Ambasta & Pravir Kumar. (2022) Cross talk mechanism of disturbed sleep patterns in neurological and psychological disorders. Neuroscience & Biobehavioral Reviews 140, pages 104767.
Crossref
Crossref
Marcin Siwek, Adrian Andrzej Chrobak, Aleksandra Gorostowicz, Anna Julia Krupa & Dominika Dudek. (2021) Withdrawal Symptoms Following Discontinuation of Vortioxetine—Retrospective Chart Review. Pharmaceuticals 14:5, pages 451.
Crossref
Crossref
Yong-liang Zhu, Shuang-long Li, Chun-yang Zhu, Wan Wang, Wen-fei Zuo & Xiang-jun Qiu. (2020) Metabolomics analysis of the antidepressant prescription Danzhi Xiaoyao Powder in a rat model of Chronic Unpredictable Mild Stress (CUMS). Journal of Ethnopharmacology 260, pages 112832.
Crossref
Crossref
Yasmine A. El-Khatib, Rabab H. Sayed, Nada A. Sallam, Hala F. Zaki & Mahmoud M. Khattab. (2020) 17β-Estradiol augments the neuroprotective effect of agomelatine in depressive- and anxiety-like behaviors in ovariectomized rats. Psychopharmacology 237:9, pages 2873-2886.
Crossref
Crossref
Funda Gulcu Bulmus, Sinan Canpolat, Zafer Sahin, Ozgur Bulmus, Ihsan Serhatlioglu & Haluk Kelestimur. (2020) Kisspeptin and RF9 prevent paroxetine‐induced changes in some parameters of seminal vesicle fluid in the male rats. Andrologia 52:4.
Crossref
Crossref
L. Holper. (2020) Optimal doses of antidepressants in dependence on age: Combined covariate actions in Bayesian network meta-analysis. eClinicalMedicine 18, pages 100219.
Crossref
Crossref
Mete Ozcan, Sinan Canpolat, Ozgur Bulmus, Nazife Ulker, Ahmet Tektemur, Suat Tekin, Sibel Ozcan, Ihsan Serhatlioglu, Emine Kacar, Ahmet Ayar & Haluk Kelestimur. (2019) Agomelatine pretreatment prevents development of hyperglycemia and hypoinsulinemia in streptozotocin-induced diabetes in mice. Fundamental & Clinical Pharmacology 33:2, pages 170-180.
Crossref
Crossref
Domenico De Berardis, Michele Fornaro, Laura Orsolini, Felice Iasevoli, Carmine Tomasetti, Andrea de Bartolomeis, Nicola Serroni, Ida De Lauretis, Gabriella Girinelli, Monica Mazza, Alessandro Valchera, Alessandro Carano, Federica Vellante, Ilaria Matarazzo, Giampaolo Perna, Giovanni Martinotti & Massimo Di Giannantonio. (2016) Effect of agomelatine treatment on C-reactive protein levels in patients with major depressive disorder: an exploratory study in “real-world,” everyday clinical practice. CNS Spectrums 22:4, pages 342-347.
Crossref
Crossref
Michael E. Thase, Natalya Danchenko, Melanie Brignone, Ioana Florea, Francoise Diamand, Paula L. Jacobsen & Eduard Vieta. (2017) Comparative evaluation of vortioxetine as a switch therapy in patients with major depressive disorder. European Neuropsychopharmacology 27:8, pages 773-781.
Crossref
Crossref
Cuiyun Li, Jing Xu, Yan Zheng, Guiling Chen, Jianmeng Wang, Liying Ma, Yan Qiao, Junqi Niu, Min Wu, Hong Zhang, Xiaojiiao Li, Hong Chen, Xiaoxue Zhu, Chengjiao Liu & Yanhua Ding. (2017) Bioequivalence and Pharmacokinetic Profiles of Agomelatine 25-mg Tablets in Healthy Chinese Subjects: A Four-Way Replicate Crossover Study Demonstrating High Intra- and Inter-Individual Variations. CHEMICAL & PHARMACEUTICAL BULLETIN Chemical and Pharmaceutical Bulletin 65:6, pages 524-529.
Crossref
Crossref
Jaya Thomas, R. Khanam & Divya Vohora. (2016) Augmentation of antidepressant effects of venlafaxine by agomelatine in mice are independent of kynurenine pathway. Neurochemistry International 99, pages 103-109.
Crossref
Crossref
Vesile Altınyazar & Nefati Kiylioglu. (2016) Insomnia and dementia: is agomelatine treatment helpful? Case report and review of the literature. Therapeutic Advances in Psychopharmacology 6:4, pages 263-268.
Crossref
Crossref